Skip to main content

Febit to Install Several SOLiD Systems for Targeted Sequencing Service

Premium

By Julia Karow

This article, originally published Sept. 28, has been updated with information from Febit.

German microarray maker Febit said this week that it will add several Applied Biosystems SOLiD sequencers and real-time PCR systems to its genomic services facility in Heidelberg in order to provide targeted sequencing services.

The deal is part of a strategic co-marketing agreement between Febit and Life Technologies, under which Febit has become a member of Life Tech's service provider programs for SOLiD and TaqMan.

Febit has already installed one SOLiD instrument and expects to start offering targeted sequencing services, which will use the firm's HybSelect sequence capture technology, within the next four to six weeks, Febit CSO Peer Stähler told In Sequence via e-mail. Once fully operational, Febit's facility aims to run more than 1,000 samples per week, according to the company.

A second SOLiD instrument is on order, Stähler said, and any further growth will depend on demand for the service.

In the future, the companies hope that customers will purchase Life Tech's SOLiD system and Febit's Geniom RT Analyzer, which runs HybSelect, along with RT PCR instrumentation, for in-house use, Stähler said. "The Febit facility with the SOLiD will serve as a show case and for conducting Febit's services and as a facility for optimization of the sequence capture/sequencing process as well as for the development of further applications, biochips, and software," he said. Customers, he added, "will be able to build a facility with the same capabilities as the Febit facility."

Febit first launched HybSelect in March, offering it initially as a product and service for use with Illumina's Genome Analyzer platform (see In Sequence 3/17/2009). A company spokesperson said that Febit outsources sequencing on the Illumina platform to partners.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.